|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
In this article, we describe the biological evaluation of a new CXCR4-targeting and -antagonizing molecule (BAT1) that we designed and show that, when incorporated into a liposomal drug delivery system, it can be used to deliver cancer therapeutics at high levels to chronic lymphocytic leukemia (CLL) cells.
|
31292126 |
2019 |
|
Hematological Disease
|
0.010 |
Biomarker
|
group |
BEFREE |
The combined capabilities to block CXCL12-induced migration and intracellular signaling while simultaneously delivering therapeutic cargo mean that the BAT1-liposome drug-delivery system could be a timely and relevant treatment of a range of hematological disorders, particularly because the therapeutic cargo can be tailored to the disease being treated.
|
31292126 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Specific uptake of BAT1-liposomes and delivery of a therapeutic cargo to the cell nucleus was seen within 3 hours of incubation and induced significantly more CLL cell death after 24 hours than control liposomes (<i>P</i> = .004).
|
31292126 |
2019 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
In this article, we describe the biological evaluation of a new CXCR4-targeting and -antagonizing molecule (BAT1) that we designed and show that, when incorporated into a liposomal drug delivery system, it can be used to deliver cancer therapeutics at high levels to chronic lymphocytic leukemia (CLL) cells.
|
31292126 |
2019 |
|
Heart Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Only BAT1 rs3853601 -22G carriers (B1 vs. C: OR = 0.5; p-value = 0.03) and IFNG rs2430561 +874AT (A vs. C: OR = 0.7; p-value = 0.03; A vs. B1+C: OR = 0.8; p-value = 0.02) showed a significant association with protection from cardiopathy in a logistic regression analysis with adjustment for gender and ethnicity; however, the association disappeared after performing adjustment for multiple testing.
|
29768622 |
2018 |
|
Marburg Virus Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Transcriptomics Reveal Antiviral Gene Induction in the Egyptian Rousette Bat Is Antagonized In Vitro by Marburg Virus Infection.
|
30400182 |
2018 |
|
Periodontal Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Here we examined whether the risk haplotype of MHC class III region BAT1-NFKBIL1-LTA and lymphotoxin-α polymorphisms associate with salivary biomarkers of periodontal disease.
|
30176756 |
2018 |
|
Psoriasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
We have identified 18 SNPs in nine genes in the HLA region (NFKBIL1, TNF-α, ATP6V1G2-DDX39B, MSH5, MICA, LTA, BAT1, and NOTCH4) and in the psoriasis susceptibility region of HLA-C as potential candidates for association with DOX cardiotoxicity.
|
28256194 |
2017 |
|
Periodontitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We identified a novel BAT1-NFKBIL1-LTA haplotype as a significant contributor to the risk of periodontitis.
|
24566624 |
2014 |
|
Ataxia
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Non-type I cystinuria associated with mental retardation and ataxia in a Korean boy with a new missence mutation(G173R) in the SLC7A9 gene.
|
20052367 |
2010 |
|
Cerebellar Ataxia
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Non-type I cystinuria associated with mental retardation and ataxia in a Korean boy with a new missence mutation(G173R) in the SLC7A9 gene.
|
20052367 |
2010 |
|
hiv-infection/aids
|
0.010 |
Biomarker
|
disease |
BEFREE |
A meta-analysis of our genomic data combined with data from the previously conducted Euro-CHAVI (Center for HIV/AIDS Vaccine Immunology) GWAS confirmed the HCP5 signal (P=3.02x10(-19)) and identified several new associations, all of them involving HLA genes: MICB, TNF, RDBP, BAT1-5, PSORS1C1, and HLA-C.
|
19115949 |
2009 |
|
Alzheimer's Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Semi-quantitative RT-PCR was also performed for BAT1 from RNA isolated from brain tissue from AD and control cases.
|
18715507 |
2008 |
|
Sensory neuropathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
BAT1 (intron 10)*2 was more common in NRTI-SN than resistant patients, but neither group differed from controls.
|
18240960 |
2008 |
|
Chagas Cardiomyopathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
BAT1, a putative anti-inflammatory gene, is associated with chronic Chagas cardiomyopathy.
|
16619187 |
2006 |
|
Lupus Erythematosus, Systemic
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of BAT1 mRNA was associated with carriers of a haplotype containing the LST1 marker transmitted to RA cases in a family study and also DRB1(*)15 associated with susceptibility to nephritis in systemic lupus erythematosus.
|
16971954 |
2006 |
|
Nephritis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Overexpression of BAT1 mRNA was associated with carriers of a haplotype containing the LST1 marker transmitted to RA cases in a family study and also DRB1(*)15 associated with susceptibility to nephritis in systemic lupus erythematosus.
|
16971954 |
2006 |
|
Hepatitis C
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The haplotype block, NFKBIL1-ATP6V1G2-BAT1-MICB-MICA, within the class III-class I boundary region of the human major histocompatibility complex may control susceptibility to hepatitis C virus-associated dilated cardiomyopathy.
|
16101831 |
2005 |
|
Diabetes
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Sections of the BAT1 promoter region were amplified from cells homozygous for the MHC haplotypes associated with susceptibility (HLA-A1, B8, DR3; 8.1 haplotype) and resistance (HLA-A3, B7, DR15; 7.1 haplotype) to diabetes and cloned into a promoter-less luciferase-encoding plasmid.
|
12653967 |
2003 |
|
Diabetes Mellitus
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Sections of the BAT1 promoter region were amplified from cells homozygous for the MHC haplotypes associated with susceptibility (HLA-A1, B8, DR3; 8.1 haplotype) and resistance (HLA-A3, B7, DR15; 7.1 haplotype) to diabetes and cloned into a promoter-less luciferase-encoding plasmid.
|
12653967 |
2003 |
|
Lysinuric Protein Intolerance
|
0.010 |
Biomarker
|
disease |
BEFREE |
Recently, the role of b(o,+)AT (SLC7A9) in cystinuria (non Type I) and the role of y(+)LAT-1 (SLC7A7) in lysinuric protein intolerance have been demonstrated.
|
11377971 |
2001 |
|
Inherited aminoaciduria
|
0.010 |
Biomarker
|
group |
BEFREE |
Defects in two genes of this family (SLC3A1, encoding rBAT and SLC7A9, encoding b(o,+)AT) are responsible for cystinuria, an inherited aminoaciduria of cystine and dibasic amino acids.
|
11396607 |
2001 |
|
Autoimmune Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Ancestral haplotypes carry haplotypic and haplospecific polymorphisms of BAT1: possible relevance to autoimmune disease.
|
1352699 |
1992 |
|
Myasthenia Gravis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The frequency of the BAT1 B allelic pattern is increased in patients with MG (n = 16) compared to an equal number of control subjects.
|
1352699 |
1992 |
|
Leprosy
|
0.020 |
Biomarker
|
disease |
BEFREE |
Interaction analysis between PARK2 and significant SNPs of anti-inflammatory/proinflammatory cytokine genes, including BAT1 to BTNL2-DR spanning the HLA (6p21.3) region in a case-control comparison, showed that the combined analysis of: (1) PARK2, tumour necrosis factor (TNF), BTNL2-DR, interleukin (IL)-10, IL-6 and TGFBR2 increased the risk towards leprosy (OR=2.54); (2) PARK2, BAT1, NFKBIL1, LTA, TNF-LTB, IL12B and IL10RB provided increased protection (OR=0.26) in comparison with their individual contribution.
|
24578538 |
2014 |